Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Details)

v3.23.1
Basis of Presentation (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 10 Months Ended
Mar. 31, 2023
Jul. 31, 2022
Apr. 30, 2023
Apr. 30, 2022
Apr. 30, 2023
Apr. 30, 2022
May 31, 2023
Basis of Presentation (Details) [Line Items]              
Operating expenses     $ 12 $ 9 $ 33 $ 34  
Net loss         37,142    
Cash in operating activities         19,945    
Working capital deficit     10,153   10,153    
Line of credit $ 8,000            
Eligible receivables percentage 10.00%            
Convertible debentures and warrant proceeds             $ 7,000
Aggregate amount             $ 30,000
Sales agreement     150,000   $ 150,000    
Convertible debenture securities percentage         10.00%    
Revolving line of credit $ 8,000            
Annual interest rate percentage 5.50%            
Outstanding balance     $ 3,354   $ 3,354    
Convertible debentures and warrants percentage         10.00%    
Securities purchase agreement percentage         10.00%    
Aggregate principal amount         $ 7,608,696    
Conversion price     $ 3.01   $ 3.01    
Warrants purchase         1,000,000    
Common stock, par value   $ 0.01 $ 0.01   $ 0.01    
Exercise price         $ 2.31    
Total purchase price     $ 7,000,000   $ 7,000,000    
Service revenue percentage   44.00% 43.00%   49.00%    
Services revenues percent     4.00%   5.00%    
Clinical services net revenue percentage     16.00% 30.00% 17.00% 34.00%  
Clinical services account receivable percentage     13.00%        
Maximum [Member]              
Basis of Presentation (Details) [Line Items]              
Clinical test information         2,470,000    
Minimum [Member]              
Basis of Presentation (Details) [Line Items]              
Clinical test information         600,000